Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.61 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21948915 | 0.84 | TYK2 (0.77) | TYK2 | |
| SCHEMBL20688655 | 0.83 | TYK2 (0.87) | TYK2JAK1STAT3JAK2CYP3A4 | |
| SCHEMBL26532383 | 0.80 | TYK2 (0.64) | TYK2 | |
| SCHEMBL20689694 | 0.79 | TYK2 (0.63) | TYK2 | |
| SCHEMBL31397950 | 0.78 | TYK2 (0.49) | TYK2JAK1STAT3JAK2CYP3A4 | |
| SCHEMBL30895715 | 0.77 | TYK2 (0.48) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| SCHEMBL21947780 | 0.76 | TYK2 (1.00) | TYK2JAK1STAT3JAK2CYP3A4 | |
| SCHEMBL29754351 | 0.76 | TYK2 (1.00) | TYK2JAK1STAT3JAK2CYP3A4 | |
| SCHEMBL26531961 | 0.75 | TYK2 (0.58) | TYK2JAK1JAK2CYP3A4CYP2C19 | |
| SCHEMBL31572586 | 0.75 | TYK2 (0.49) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221453-B2 | Substituted pyrazolo[5′,1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-11 | — | — | US | disclosed |
| CN-118084920-A | Five membered heteroaromatic pyrimidine-3-carboxamide derivatives, compositions and uses thereof | 镇江圣安医药有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230110996-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS TYK2 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11414431-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors | NIMBUS LAKSHMI, INC. (US) | 2022-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110996-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS TYK2 INHIBITORS | TYK2, JAK1, MATK | TYK2 1/4885JAK1 2/4885STAT3 489/4885 |
| US-11414431-B2 | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors | TYK2, JAK1, JAK2 | TYK2 1/4885JAK1 2/4885STAT3 615/4885 |
| US-12221453-B2 | Substituted pyrazolo[5′,1′:2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors | TYK2, JAK1, JAK2 | TYK2 1/4885JAK1 2/4885STAT3 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.